Article Text

Chemotherapy-induced peripheral neuropathy: highlighting unmet needs
  1. Susanna B Park
  1. Correspondence to Dr Susanna B Park, Brain and Mind Centre, Sydney Medical School, The University of Sydney, Sydney, NSW 2050, Australia; susanna.park{at}

Statistics from

Chemotherapy-induced peripheral neuropathy may be under-recognised in cancer survivors and require better management strategies

With an estimated 32 million cancer survivors worldwide,1 it is increasingly important to understand the potential long-lasting impacts of successful cancer treatments. Neurological side effects of chemotherapy, including chemotherapy-induced peripheral neuropathy (CIPN), often produce persistent symptoms affecting sensation and balance in cancer survivors. Despite successful cancer treatment and long-term survival prospects, survivors may be left with long-term functional disability and reduced quality of life.2 In the current issue of JNNP, Shah and colleagues3 examine the incidence of CIPN in a population-based cohort—highlighting the need for greater insights into CIPN risk factors, management and treatment options.

While many studies have focused on the incidence of CIPN in a cancer-specific or chemotherapy-specific population, Shah and colleagues3 used a population-based approach, …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.